Sanofi Reports 3Q09 Annualized Lovenox Sales of $4.4B
[Sanofi’s reporting currency is the Euro, but the growth rates reported below are in local currencies unless otherwise specified. Tallying growth in local currencies is a way to track the change in volume and price irrespective of exchange rates. The figures below are annualized, i.e. they are 4x the reported 3Q09 numbers.]
Worldwide Lovenox sales rose 14% year-over-year (18% in Euros) to an annualized rate of €3.0B, which is $4.4B at the current exchange rate.
In the US (where MNTA and NVS have filed an application to sell generic Lovenox), annualized 3Q09 Lovenox sales rose 8% in dollars to $2.6B.
The breakdown of 3Q09 sales by geography is as follows (growth rates are year-over-year in local currencies):
US: €1.77B (59% of total), 8% growth EU: €880M (29% of total), 23% growth RoW: €330M (11% of total), 19% growth === Total: €2.99B, 14% growth
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.